Research ArticleArticle
Simultaneous physiologically-based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin
Helen Gu, Catherine Dutreix, Sam Rebello, Taoufik Ouatas, Lai Wang, Dung Yu Chun, Heidi J Einolf and Handan He
Drug Metabolism and Disposition November 8, 2017, dmd.117.078006; DOI: https://doi.org/10.1124/dmd.117.078006
Helen Gu
1 Novartis Institutes for Biomedical Research;
Catherine Dutreix
2 Novartis Oncology
Sam Rebello
1 Novartis Institutes for Biomedical Research;
Taoufik Ouatas
2 Novartis Oncology
Lai Wang
1 Novartis Institutes for Biomedical Research;
Dung Yu Chun
2 Novartis Oncology
Heidi J Einolf
1 Novartis Institutes for Biomedical Research;
Handan He
1 Novartis Institutes for Biomedical Research;
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Simultaneous physiologically-based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin
Helen Gu, Catherine Dutreix, Sam Rebello, Taoufik Ouatas, Lai Wang, Dung Yu Chun, Heidi J Einolf and Handan He
Drug Metabolism and Disposition November 8, 2017, dmd.117.078006; DOI: https://doi.org/10.1124/dmd.117.078006
Research ArticleArticle
Simultaneous physiologically-based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin
Helen Gu, Catherine Dutreix, Sam Rebello, Taoufik Ouatas, Lai Wang, Dung Yu Chun, Heidi J Einolf and Handan He
Drug Metabolism and Disposition November 8, 2017, dmd.117.078006; DOI: https://doi.org/10.1124/dmd.117.078006
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement